# Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer

## TL;DR

This study found that men and women with bladder cancer have similar outcomes after surgery when treated in a specialized center with standardized care.

## Contribution

The study shows that gender disparities in bladder cancer survival can be reduced with timely, standardized treatment in expert centers.

## Key findings

- Men and women had similar cancer control and survival rates after radical cystectomy.
- No significant differences were found in disease-free, disease-specific, or overall survival between genders.
- Standardized care in high-volume centers may reduce historical survival gaps between men and women.

## Abstract

This study looked at whether men and women with bladder cancer have different outcomes after their bladder is surgically removed in a specialised cancer centre. Although women with bladder cancer are often thought to have more advanced disease and worse survival, this is not always due to the cancer itself and may be influenced by delays in diagnosis or differences in access to specialist care. In this large single-centre study, men and women received similar investigations, treatments, and types of surgery and had comparable tumour features at the time of operation. The results showed no meaningful differences between men and women in cancer control or survival after surgery, suggesting that when both sexes receive timely, standardised care in a high-volume expert centre, long-standing survival gaps between men and women can be greatly reduced.

Background: Female patients undergoing radical cystectomy (RC) for bladder cancer have historically presented with more advanced disease and poorer survival outcomes than males. These disparities have been attributed to biological differences, delayed diagnosis, and variations in treatment delivery. Recent data suggest, however, that outcomes may converge when patients are managed in standardized, multidisciplinary, high-volume centers. This study evaluated the influence of gender on perioperative features and oncological outcomes such as disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS) at a tertiary uro-oncology center. Methods: We retrospectively reviewed a prospectively maintained database of patients who underwent open or robotic-assisted RC for histologically confirmed urothelial carcinoma between 2014 and 2023 at Guy’s and St. Thomas’ NHS Foundation Trust. Demographic, perioperative, and pathological variables were stratified by gender to assess their association with DFS, DSS, and OS. Results: A total of 887 patients were included: 640 men (72.2%) and 247 women (27.8%), with similar mean age (68.5 vs. 68.1 years) and tumour histology (pure urothelial carcinoma 85% vs. 83%). Men had a higher prevalence of diabetes and chronic kidney disease, but no significant differences were observed in time from referral to surgery (0.93 vs. 1.03 months, p = 0.93), use of neoadjuvant therapy (21.6% vs. 17.3%, p = 0.25), or surgical approach (p = 0.55). Pathological stage distribution was comparable between sexes (pT0–1: 44% vs. 50%; pT2–4: 56% vs. 50%; p = 0.13). Kaplan–Meier analysis revealed no significant gender-related differences in 12-month DFS (77.3% vs. 75.4%, p = 0.20), DSS (85.6% vs. 86.9%, p = 0.56), or OS (81.2% vs. 85.2%, p = 0.70). Conclusion: In this high-volume tertiary center, gender did not independently influence perioperative or survival outcomes following radical cystectomy. These findings suggest that standardized, multidisciplinary management within specialized bladder cancer pathways may mitigate the pathological and survival disparities historically associated with gender.